2Rouzier R, Perou CM, Symmans -W-F, et al. Breast cancer molecular subtypes respond differendy to preoperative chemotherapy[J]. Clin Cancer Res, 2005, 11(16): 5678-5685.
3Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment[J].Clin Cancer Res, 2004, 10(19) : 6622-6628.
4Arriola E, Moreno A, Varela M, et al. Predictive value of HER-2 and Topoisomerase Ⅱ lpha in response to primary doxorubicin in breast cancer[J] . EurJ Cancer, 2006, 42(17): 2954-2960.
5Conforti R, Boulet T, Tomasic G, et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials[J]. Ann Oncol, 2007, 18(9): 1477-1483.
6ChangJC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer[J]. Lancet, 2003, 362(9381): 362-369.
7Kaufrnann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations[J].J Clin Oncol, 2003, 21(13): 2600-2608.
8Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer[J]. BrJ Cancer,2002, 86(7): 1041-1046.
9Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res, 2007, 13(8): 2329-2334.
10Livasy GA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma[J]. Mod Pathol,2006, 19(2): 264-271.
